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y 1139-61 Is the Sirolimus Drug Eluting Stent Better Than 
Paclitaxel Coated Stent in "Real Life" Environment?
Jean-Christophe E. Stauffer, Esq., Charles Seydoux, Esq., Jean-Jacques Goy, Esq., 
Clinic Cecil, Lausanne, Switzerland
Background: Active stents seems to improve the outcome after percutaneous interven-
tion (PCI) in reducing MACE at 9 months. However no prospective data comparing vari-
ous devices are available.
Method: Since March 2003, all patients suitable for stent implantation were randomized
to receive either a sirolimus eluting stent (SES) or a paclitaxel active stent (PAS). Stan-
dard procedures were performed. Aspirin and clopidogrel were initiated for at least one
year. Clinical outcome (MACE incidence at 9 months) is the primary end-point. Control
angiography was performed only when clinically driven.
Results: A total of 102 pts were included (mean age 66±11), (24 female), received a 54
SES and 48 a PAS. Demographic data were comparable with a proportion of 8 pts with
unstable angina. Diabetes was present in 7 pts the SES group and in 6 pts in the PAS
group. Baseline data and follow-up at 3 months are presented in the table below:The inci-
dence of MACE did not differ after a mean follow-up of 3 ±4 months between the 2
groups. Particularly no pt died in either group. MI did not occur either. Only sub-acute
thrombosis was documented in 2 pts in the PAS group. TLR and TVR were required in 0
pts in the SES group versus 2 pts in the PAS group.
Conclusion: There was no significant difference in the incidence of MACE between siroli-
mus and paclitaxel group during this short follow-up. Nine-month follow-up will be avail-
able at time of presentation.
1139-62 Sirolimus Coated Stent Implantation Versus 
Intracoronary Beta-Irradiation for the Treatment of De 
Novo Lesions
Christoph K. Naber, Karl Wegscheider, Katja Brauck, Holger Eggebrecht, Dietrich 
Baumgart, Axel Schmermund, Dirk Boese, Raimund Erbel, University Hospital, Essen, 
Germany, Insitute for Statistics and Oeconometry, Hamburg, Germany
Introduction: Antiproliferative strategies for the reduction of restenosis such as vascular
brachytherapy (VBT) and drug-eluting Stents have proven to be safe and highly effective.
While VBT is effective for the treatment of in-stent restenosis, the data for the treatment
of de-novo lesions are less convincing. This study aimed to compare the safety and effi-
cacy of VBT and Sirolimus-eluting Stents (Cypher) for the treatment of de-novo lesions.
Methods: 53 individuals with de-novo lesions were treated with PTCA and Cypher-Stent
Implantation. Matching was performed with the cohort of patients with de-novo lesions
from the European RENO registry. This registry included the first 1098 patients treated
with intracoronary beta-irradiation (Sr90) in Europe. 123 patients met the matching crite-
ria. Angiographic results and MACE rates (death, MI, TVR, TLR) were compared after 6
months.
Results: There were more diabetics in the Cypher-Stent group (32.1 vs. 19.5%; p=0.07)
and more patients with multivessel disease (83.0 vs. 56.1%; p<0.001). Lesion length
(13.3±4.1 vs. 13.2±3.9 mm) and reference diameter (3.1±0.5 vs. 3.0±0.5 mm) were com-
parable. Mean radiation dose in the RENO patients was 18.2±3.1 Gy, geographic miss
occurred in 6.5%. New Stents were implanted in 94 RENO patients (76.4%).
After 6 months the overall MACE (21.1% vs. 7.5%; p=0.03) and binary restenosis rates
(30.7 vs. 11.8; p=0.01) were significantly higher in the RENO group when compared with
the Cypher patients. This was irrespective whether a new-stent was implanted or not.
Conclusion: the use of vascular brachytherapy for the treatment of de-novo lesions can-
not be recommended. In these cases, the implantation of drug-eluting stents is clearly
favourable.
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843-1 REDOX Trial - Reduced Sirolimus Doses on the Bx 
VELOCITYTM Stent Four-Month Results
J. Eduardo Sousa, Alexandre Abizaid, Fausto Feres, Luiz A. Mattos, Luiz F. Tanajura, 
Amanda G.M.R. Sousa, Jeffrey Popma, Peter Fitzgerald, Joseph-Anthony Giorgianni, 
Roxanne A. Rodney, Instituto Dante Pazzanese de Cardiologia, Sao Paolo, Brazil
Background: The CypherTM Sirolimus-eluting Coronary Stent has demonstrated a sig-
nificant reduction in late loss and restenosis in four randomized trials. The next genera-
tion of drug-eluting stents are being developed with new materials which have potentially
less surface area. For this reason there is a need to understand the effect of reducing the
amount of drug on the stent. A trial was conducted to assess the safety and efficacy of
two reduced sirolimus doses on the Bx VELOCITY™ stent, in patients with de novo
native coronary artery lesions.
Method: A double blind, randomized study of the sirolimus-eluting Bx VELOCITY™ stent
containing 45% or 70% of the current sirolimus dose (140 mcg/cm2) was conducted in 60
patients (40 non-diabetic/20 diabetic) with de novo native coronary artery lesions <
18mm in length and in vessels >3.0mm to <3.5mm in diameter. Four month angio and
IVUS were performed.
Results: The 4-month follow-up TVF, TLR and MACE rates were zero for both groups.
The table is a comparison of the angiographic results from the FIM and REDOX trials.
Conclusion: The results of the two reduced doses of sirolimus on the Bx VELOCITYTM
stent are the same and are similiar to those of the Cypher stent used in the FIM trial.
These data suggest efficacy is maintained when reducing the total sirolimus dose on the
Bx VELOCITYTM.
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843-2 Everolimus-Eluting Stents for the Prevention of 
Restenosis: Results of the FUTURE II Trial
Eberhard Grube, Ricardo A. Costa, Roxana Mehran, Manuela Negoita, Yeal Gilutz, 
Yoshihiro Tsuchiya, Martin Fahy, Ecaterina Cristea, Bahram Sahid, Horia Marginean, 
Ralf Muller, Georg Techen, Michael Rinck, Alexandra J. Lansky, Karl Eugen Hauptmann, 
Hans Storger, Cardiovascular Research Foundation, New York, NY, Heart Center, 
Siegburg, Germany
In the first-in-man experience, the everolimus-eluting stent (EES) demonstrated safety,
feasibility and effectiveness to inhibit neointimal proliferation in human coronary arteries.
The FUTURE II trial is a larger, prospective, randomized, blinded multicenter study of the
EES (with a bioabsorbable polymer coating) vs. metallic stent (MS). We report the 6-
month clinical and angiographic results.
Methods and Results: 64 patients (65 lesions) were randomized in a 1:2 ratio to EES
(n=21) vs. MS (n=43). Baseline clinical and angiographic characteristics were similar in
both groups, with 26.6% diabetics, mean vessel size of 2.95±0.48mm and lesion length
of 11.43±3.44mm. Final and 6-month angiographic and clinical results are shown in the
Table. Conclusions: The expanded FUTURE II trial confirmed the efficacy demonstrated
in the FUTURE I trial with a significant 85.9% reduction in neointimal proliferation (in-
stent late loss) with EES compared to the bare metal stent. There was no exaggerated
hyperplasia at the proximal and/or distal edges of the stent in the everolimus group.
LAD CX RCA MACE
SES 21 12 21 2%
PAS 23 9 16 4%
Angiographic - 4 Month Follow-up
FIM – Slow 
Release
45% Sirolimus 
Dose
70% Sirolimus 
Dose
In-stent MLD, mm 2.85±0.46 2.74±0.39 2.65±0.48
In-stent DS, % 5.0±6.7 3.3±8.0 7.7±13.5
In-stent late loss, mm 0.09±0.25 0.10±0.31 0.10±0.35
In-stent binary restenosis, % 0.0 0.0 3.6 (1)
